<![CDATA[Pharma — December 2025]]>The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. https://proinvestor.com/investornyt/1390543/the-healthcare-sector-is-surging-heres-1-stock-every-investor-should-have-on-their-radar

]]>https://dev.proinvestor.com/forum/topic/400905/pharma-december-2025RSS for NodeSun, 07 Jun 2026 06:30:42 GMTSat, 06 Dec 2025 15:11:58 GMT60<![CDATA[Reply to Pharma — December 2025 on Fri, 19 Dec 2025 11:16:39 GMT]]>Novo: Flere medicinalselskaber rygtes på vej til at indgå aftaler om lavere priser i USA https://proinvestor.com/investornyt/1395434/novo-flere-medicinalselskaber-rygtes-pa-vej-til-at-indga-aftaler-om-lavere-priser-i-usa

]]>https://dev.proinvestor.com/forum/post/8038345https://dev.proinvestor.com/forum/post/8038345Fri, 19 Dec 2025 11:16:39 GMT<![CDATA[Reply to Pharma — December 2025 on Mon, 08 Dec 2025 05:17:24 GMT]]>Lundbeck viser langvarig virkning med middel mod svære epilepsilidelser https://proinvestor.com/investornyt/1390914/lundbeck-viser-langvarig-virkning-med-middel-mod-svaere-epilepsilidelser

]]>https://dev.proinvestor.com/forum/post/8038344https://dev.proinvestor.com/forum/post/8038344Mon, 08 Dec 2025 05:17:24 GMT<![CDATA[Reply to Pharma — December 2025 on Sun, 07 Dec 2025 09:28:38 GMT]]>
Link Preview Image
Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting

· New long-term data presented at AES 2025 indicate reductions in seizure frequency are

favicon

News Powered by Cision (news.cision.com)

]]>https://dev.proinvestor.com/forum/post/8038343https://dev.proinvestor.com/forum/post/8038343Sun, 07 Dec 2025 09:28:38 GMT<![CDATA[Reply to Pharma — December 2025 on Sun, 07 Dec 2025 09:28:20 GMT]]>Lundbeck. Positive resultater med nyt epilepsimiddel

]]>https://dev.proinvestor.com/forum/post/8038342https://dev.proinvestor.com/forum/post/8038342Sun, 07 Dec 2025 09:28:20 GMT